Supravenous discoloration of the skin due to docetaxel treatment

被引:16
作者
Schrijvers, D [1 ]
Van den Brande, J [1 ]
Vermorken, JB [1 ]
机构
[1] Univ Hosp Antwerp, Dept Med Oncol, B-2650 Edegem, Belgium
关键词
D O I
10.1046/j.1365-2133.2000.03518.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
引用
收藏
页码:1069 / 1070
页数:2
相关论文
共 7 条
[1]  
BERNSTEIN T, 1977, NEW ENGL J MED, V297, P337
[2]  
DESPAIN JD, 1992, SEMIN ONCOL, V19, P501
[3]  
FINE D, 1986, ARCH DERMATOL, V122, P199
[4]   Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer [J].
Hainsworth, JD ;
Burris, HA ;
Erland, JB ;
Thomas, M ;
Greco, FA .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) :2164-2168
[5]  
HRUSHESKY WJ, 1980, CUTIS, V26, P181
[6]   Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment [J].
Semb, KA ;
Aamdal, S ;
Oian, P .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) :3426-3432
[7]   DOCETAXEL (TAXOTERE(R)), A REVIEW OF PRECLINICAL AND CLINICAL-EXPERIENCE .2. CLINICAL-EXPERIENCE [J].
VANOOSTEROM, AT ;
SCHRIIVERS, D .
ANTI-CANCER DRUGS, 1995, 6 (03) :356-368